Risk factors for invasive aspergillosis in living donor liver transplant recipients

Makoto Osawa, Yutaka Ito, Toyohiro Hirai, Rie Isozumi, Shunji Takakura, Yasuhiro Fujimoto, Yoshitsugu Iinuma, Satoshi Ichiyama, Koichi Tanaka, Michiaki Mishima – 29 March 2007 – Invasive aspergillosis (IA) is a severe complication of liver transplantation. Risk factors for IA after deceased donor liver transplantation (DDLT) have been presented in several reports, but are not well established for living donor liver transplant recipients. Here, a retrospective case‐control study was performed.

B‐cell surface marker analysis for improvement of rituximab prophylaxis in ABO‐incompatible adult living donor liver transplantation

Hiroto Egawa, Katsuyuki Ohmori, Hironori Haga, Hiroaki Tsuji, Kimiko Yurugi, Aya Miyagawa‐Hayashino, Fumitaka Oike, Akinari Fukuda, Jun Yoshizawa, Yasutsugu Takada, Koichi Tanaka, Taira Maekawa, Kazue Ozawa, Shinji Uemoto – 29 March 2007 – Although the effectiveness of rituximab has been reported in ABO blood group (ABO)‐incompatible (ABO‐I) organ transplantation, the protocol is not yet established.

Functional and morphological comparison of three primary liver cell types cultured in the AMC bioartificial liver

Paul P.C. Poyck, Ruurdtje Hoekstra, Albert C.W.A. van Wijk, Chiara Attanasio, Fulvio Calise, Robert A.F.M. Chamuleau, Thomas M. van Gulik – 29 March 2007 – The selection of a cell type for bioartificial liver (BAL) systems for the treatment of patients with acute liver failure is in part determined by issues concerning patient safety and cell availability. Consequently, mature porcine hepatocytes (MPHs) have been widely applied in BAL systems. The success of clinical BAL application systems is, however, largely dependent on the functionality and stability of hepatocytes.

Distinct effects of surgical denervation on hepatic perfusion, bowel ischemia, and oxidative stress in brain dead and living donor porcine models

Markus Golling, Cosima Jahnke, Hamidreza Fonouni, Rezvan Ahmadi, Renate Urbaschek, Raoul Breitkreutz, Peter Schemmer, Thomas W. Kraus, Martha M. Gebhard, Markus W. Büchler, Arianeb Mehrabi – 29 March 2007 – The liver function and perfusion following brain death is mainly influenced by the sympathetic nerves and hormones. We examined the specific influence of surgical liver denervation on systemic and hepatic perfusion parameters, bowel ischemia and oxidative stress in hemodynamically stable BD and control (living donor [LD]) pigs.

Value of the critical flicker frequency in patients with minimal hepatic encephalopathy

Manuel Romero‐Gómez, Juan Córdoba, Rodrigo Jover, Juan A. del Olmo, Marta Ramírez, Ramón Rey, Enrique de Madaria, Carmina Montoliu, David Nuñez, Montse Flavia, Luis Compañy, José M. Rodrigo, Vicente Felipo – 28 March 2007 – Minimal hepatic encephalopathy (MHE) is mainly diagnosed using psychometric tests such as the psychometric hepatic encephalopathy score (PHES). Despite the clinical and social relevance of MHE, psychometric testing is not widespread in routine clinical care.

Loss of integrin linked kinase from mouse hepatocytes in vitro and in vivo results in apoptosis and hepatitis

Vasiliki Gkretsi, Wendy M. Mars, William C. Bowen, Lindsay Barua, Yu Yang, Lida Guo, René St.‐Arnaud, Shoukat Dedhar, Chuanyue Wu, George K. Michalopoulos – 28 March 2007 – Extracellular matrix (ECM) is fundamental for the survival of cells within a tissue. Loss of contact with the surrounding ECM often causes altered cell differentiation or cell death. Hepatocytes cultured without matrix lose patterns of hepatocyte‐specific gene expression and characteristic cellular micro‐architecture.

Biliary epithelial‐mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis

Helen Robertson, John A. Kirby, William W. Yip, David E.J. Jones, Alastair D. Burt – 28 March 2007 – Primary biliary cirrhosis (PBC) recurs in the allograft after liver transplantation. Study of early tissue changes in the time‐course of disease recurrence provides a unique insight into the initial stages of the disease process, which, in nontransplant patients, occurs long before clinical presentation. We describe a patient who developed classical clinical, biochemical, immunological, and histological features of PBC within 9 months after transplantation.

Subscribe to